Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma

<div>(a) Kaplan-Meier survival for OS of patients in both groups from the GEO data. (b) AUC of time-dependent ROC curves confirmed that our risk model has predictive property. (c) Distribution and correlation of survival time, survival status, and risk score of patients from GEO data. (d) t-SNE and PCA analysis confirmed the distribution of patients in both groups from GEO data.</div>

Disease Markers

fig4

Figure 4

Figure 4: Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma 

Figure 4 | Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma 